Literature DB >> 27460479

ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin.

Muhammad Bilal Abid1, Shi Wang2, Hoi Yin Loi3, L M Poon4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27460479     DOI： 10.1007/s00277-016-2746-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  3 in total

1.  Brentuximab-vedotin maintenance following chemotherapy without irradiation for primary intracranial embryonal carcinoma in down syndrome.

Authors:  Mohammad H Abu Arja; Suzanne E Conley; Violeta Salceda; Fahd Al-Sufiani; Daniel R Boué; Jonathan L Finlay
Journal:  Childs Nerv Syst       Date:  2017-12-13       Impact factor: 1.475

2.  Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement.

Authors:  Charlotte Rigaud; Samuel Abbou; Stephane Ducassou; Mathieu Simonin; Lou Le Mouel; Victor Pereira; Stephanie Gourdon; Anne Lambilliotte; Birgit Geoerger; Veronique Minard-Colin; Laurence Brugieres
Journal:  Haematologica       Date:  2022-09-01       Impact factor: 11.047

3.  Central nervous system relapse in a child with anaplastic large cell lymphoma: potential for new therapeutic strategies.

Authors:  Enass H Raffa; Helen M Branson; Bo Ngan; Sarah Alexander; Oussama Abla
Journal:  Cancer Rep (Hoboken)       Date:  2021-04-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.